{
  "docId": "019de512-188f-75bd-b9c3-b699923bd74c",
  "docSlug": "b87a8eceb8fdc0b05f41052c19d68b16",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Adagio Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 19,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 14,
  "notes": "The table uses a color-coded heatmap to represent IC50 values, with red indicating higher potency (lower IC50).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de512-188f-75bd-b9c3-b699923bd74c/8",
  "deckHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c",
  "deckJsonHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c.json",
  "deckAnchorHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.12,
        "x": 0.83,
        "y": 0.24
      },
      "kind": "chart",
      "text": "IC50 legend",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "096ec74f-8e7a-4d05-8bf5-27d28b92b881",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.02,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "There are no head-to-head trials between ADG20 and the other products referenced on this slide. No comparisons can be made between product efficacy or safety. ADG20 is an investigational therapy.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f0da76a-2a58-45ed-b60e-6f9d9b75d633",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.15,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "image",
      "text": "Company logos for ADG, GSK, VIR, Regeneron, Lilly, AstraZeneca",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2570165f-703a-4a30-b151-136cecbac259",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.02,
        "y": 0.78
      },
      "kind": "source-note",
      "text": "Cell 2021, 184:2939-2954.e9; Cell 2021, 184:4220-4236.e13; Planas, D., et al. Nature (2021).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba8e9fef-1571-45cc-97c0-782a9bca08b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.35,
        "x": 0.2,
        "y": 0.22
      },
      "kind": "table",
      "text": "Heatmap table of IC50 values for antibodies ADG20, S309, REGN10933, REGN10987, LY-CoV555, LY-CoV16, AZD1061, AZD8895 against Victoria and Alpha variants.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ba9c52f-fd30-4a34-a71c-61f5c86cc261",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "ADG20 shows broad yet variable neutralizing activity against all variants of concern",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a15212dd-797a-4228-a916-035b540ba20e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "In vitro neutralization of antibodies in clinical development versus variants of concern",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5cb6ec3e-4655-4b44-b677-14706ac0e15b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "da5bfe80-32f4-45d7-b1d2-d6174b64614f",
      "evidence": "Comparison of antibody efficacy across variants",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 5,
      "beatId": "6a1a205b-c7b3-4004-94f2-1eab1f50d86f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document agitates the problem through multiple tables and data points, highlighting the challenge of COVID-19 variants.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "367a8c0e-d39d-4694-aace-945e8b5a0e36",
      "evidence": "The document implies the cost of inaction through its emphasis on the challenge of COVID-19 variants and the need for effective treatments.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing COVID-19 variants?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}